GLP-1 Spending Hit $5.8 Billion in 2022 for U.S. Adults Without Diabetes
Summary by MedPage Today
4 Articles
4 Articles
All
Left
Center
1
Right


GLP-1 Spending Hit $5.8 Billion in 2022 for U.S. Adults Without Diabetes
(MedPage Today) -- The number of U.S. adults without diabetes using GLP-1 receptor agonists more than tripled from 2018 to 2022, boosting annual spending from $1.6 billion to $5.8 billion, survey data showed. Based on an unweighted sample of nearly...
·New York, United States
Read Full ArticleCoverage Details
Total News Sources4
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage